Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of NEUROPHARMAGEN pharmacogenetic test in the selection of
the pharmacological treatments for patients with Major Depressive Disorder (MDD), both with
and without psychiatric comorbidities. Patients will be randomly asigned to test-guided
treatment prescription or to treatment as usual ina a 1:1 ratio; the results of the test will
not be disclosed to the later until the end of the 3-month follow-up period. The study will
compare the rate of treatment responders among both groups, based on patient-reported
improvement collected by blind telephone interview.